In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver ...

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

Investing.com -- Edgewise Therapeutics Inc (NASDAQ:EWTX) stock rose 4.8% in premarket trading Wednesday after the company announced positive updates from its ongoing Phase 2 clinical trial of EDG-7500 ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

The use of the preCARDIA system appears safe and feasible for patients with acute decompensated heart failure, with notable reductions in cardiac filling pressures and increased urine output.

Bayer receives Japanese approval for finerenone to treat patients with chronic heart failure: Berlin Tuesday, December 23, 2025, 14:00 Hrs [IST] Bayer announced that Japan’s Min ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

Cytokinetics, Incorporated CYTK announced that the FDA approved its lead pipeline candidate, aficamten, for the treatment of ...

Employer-sponsored family coverage now averages nearly $27,000 per year in the U.S., with workers paying more through higher premiums and deductibles. Recent federal changes threaten to reverse New ...

Background Predicting progression to aortic valve replacement (AVR) in moderate aortic stenosis (AS) is challenging. This ...